Drug Trial Radar · NCT07183306
A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
86
Actual
Start
Dec 30, 2024
Primary completion
Aug 24, 2027
Study completion May 3, 2028
Sponsor
- Lead sponsor
- Suzhou HepaThera Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is A multicenter, open-label, partial multiple-ascending doses phase1b/2 in which participants with chronic hepatitis B virus (HBV) infection will receive HT-101 and/or HT-102 and be assessed for safety, tolerability, Pharmacokinetics, and Pharmacodynamics. Approximately 86 patients with chronic hepatitis B infection were planned to be recruited. Among them, Group A and Group AA received HT-101 injection, administered once every 4 weeks (Q4W), at least for 24 weeks. Group B received HT-102 injection, administered Q4W for 24 weeks and sequential dosed with HT-101 for another 24 weeks. Groups C, D, and E received HT-101 injection combined with HT-102 injection, administered once every 4 weeks for 24weeks. During the study period, all subjects received nucleoside (acid) analogues (NAs) treatment.
Conditions
- Chronic Hepatitis B
Interventions
HT-101Drug
HT-101 given by subcutaneous injection.
HT-102Drug
HT-102 given by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinically significant abnormalitiesTime frame: From enrollment to the end of treatment at up to 60 weeks
- Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: From enrollment to the end of treatment at up to 60 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, China
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, Fujian, China
Guangzhou Eighth People's Hospital, Guangzhou Medical University
Guangzhou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
Qingyuan People's Hospital
Qingyuan, Guangdong, China
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.